KONTAN.CO.ID - JAKARTA - Pfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into clinical trials later this year, the company said on Thursday, after it dropped development of an earlier daily-form of the drug last year. The new drug is part of the second-generation of weight-loss pills, under development by companies including Eli Lilly and Novo Nordisk, that will offer patients a more convenient dosing instead of injections. Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, to be worth over $150 billion by the early 2030s.
Pfizer Moves Forward With Once-daily Weight Loss Pill After Scrapping Earlier Version
KONTAN.CO.ID - JAKARTA - Pfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into clinical trials later this year, the company said on Thursday, after it dropped development of an earlier daily-form of the drug last year. The new drug is part of the second-generation of weight-loss pills, under development by companies including Eli Lilly and Novo Nordisk, that will offer patients a more convenient dosing instead of injections. Some analysts expect the weight-loss drug market, currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, to be worth over $150 billion by the early 2030s.